Early Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a slow-growing B-cell or T-cell blood cancer called Non-Hodgkin lymphoma (including lymphomas affecting the skin), or a type of Non-Hodgkin lymphoma with a variable course such as mantle cell lymphoma, with measurable signs of disease
- People diagnosed with certain rare conditions involving abnormal immune or histiocyte cells, specifically Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or Rosai-Dorfman disease (RDD) (confirm with trial site)
- People diagnosed with MGUS, smouldering multiple myeloma, or multiple myeloma as defined by international guidelines (confirm with trial site)
- People diagnosed with certain solid tumours, such as lung cancer, meningioma, adrenal gland tumours including cortisol-producing growths, or cases where a tumour is strongly suspected, such as in Cushing's disease
- People whose cancer is newly diagnosed and untreated, has not responded to previous treatment, or has come back after treatment
- People aged 18 or older
- Women of childbearing potential who have a negative pregnancy test from a blood sample taken within 2 weeks before joining the study, or a negative urine pregnancy test on the day of the procedure
- People who are patients at Memorial Sloan Kettering Cancer Center (MSKCC)
Who may not be able to join:
- People who are currently breastfeeding
- People with a history of serious kidney problems, specifically chronic kidney disease where kidney function (eGFR) is measured at below 30 (confirm with trial site)
- People who are unable or unwilling to undergo the scanning procedure, for example due to claustrophobia
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Anton Nosov, MD, Memorial Sloan Kettering Cancer Center
Phone: 212-639-8575
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Tumor standard uptake value (SUV)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.